ImmunoVeg begins its incubation journey with Bio4Dreams
12 November 2026
/
Following the 2026 Ennio Ongini Award, ImmunoVeg, a biotech company producing plant-derived bioactive molecules, begins incubation with Bio4Dreams.
ImmunoVeg, a biotech company specialising in the production of plant-derived bioactive molecules, is beginning its incubation journey with Bio4Dreams following its receipt of the 2026 Ennio Ongini Award.
Originating from research conducted at the University of Naples Federico II and the National Research Council (CNR), ImmunoVeg operates in the field of plant biotechnology, primarily using plant cell cultures as platforms for producing bioactive compounds.
Through molecular farming technologies and controlled cultivation systems, the company develops solutions to produce natural extracts and biomolecules more sustainably and predictably, with potential applications in areas including nutraceuticals, cosmetics and food.
In May 2026, during the BioInvestIT 2026 final in Milan, ImmunoVeg received the Ennio Ongini Award, now in its third edition. The award includes one year of membership in the Bio4Dreams ecosystem and an incubation programme with dedicated business development services, worth a total of €15,000.
With the signing of the incubation agreement, ImmunoVeg now joins the Bio4Dreams ecosystem, officially beginning the programme included in the award.
📗 Discover more about ImmunoVeg and the other companies in our portfolio.
Last updates
12 Nov 26
ImmunoVeg begins its incubation journey with Bio4Dreams
Following the 2026 Ennio Ongini Award, ImmunoVeg, a biotech company producing plant-derived bioactive molecules, begins incubation with Bio4Dreams.
12 Nov 26
With UniTS to advance Life Sciences research
Partnership with the University of Trieste to promote technology transfer and new entrepreneurial opportunities in the Life Sciences.
10 Nov 26
Digital Twin at Work: project presentation at MIND
On 26 November, Bio4Dreams and Federated Innovation @MIND will present Digital Twin at Work, a project focused on the Digital Human Twin in cardiology.